Brain Tumor Center Tests More than 2,000 Compounds in Search of New Glioblastoma Treatment

Researchers at the Brain Tumor Center at the University of Cincinnati (UC) Neuroscience Institute are throwing almost everything but the kitchen sink at an aggressive type of brain tumor that has proved stubbornly resistant to conventional forms of treatment. In a novel, investigator-initiated study, James Driscoll, MD, PhD, and his team are testing more than 2,000 different small-molecule compounds for signs of effectiveness in the treatment of the high-grade glioma tumor known as glioblastoma multiforme.

They have quickly developed a high-throughput, automated screen to rapidly test hundreds of compounds at the same time. And although not yet prepared to discuss the results, Dr. Driscoll says he hopes to be able to pursue funding for a phase-1 clinical trial involving one or more of the compounds within the next 12 months. The trial would take place at the Brain Tumor Center, a center of excellence within the UC Neuroscience Institute and the UC Cancer Institute. Both institutes are part of the UC College of Medicine and UC Health. For more information, click here to read the full release.